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Abstract
Objectives—Bisphosphonates (BPN) have actions on a variety of cell types including: osteoclasts,
osteoblasts, osteocytes, and endothelial cells. The objectives of this report are to review the current
state of understanding of the effects of BPNs on orthodontic tooth movement and to provide evidence
on BPN's in vivo effects on bone marrow derived osteoprogenitor cells.
Material & Methods—Mice from the C3H/HeJ (C3H), C57BL/6J (B6), FVB/NJ (FVB) and
BALB/cByJ (BALB) strains were treated for 3-weeks with 0, 3, 30, or 150 mcg/kg/week alendronate
(ALN) administered s.c. alone or in combination with 50ppm fluoride (F). Bone marrow cells were
harvested and subjected to in vitro CFU-F and CFU-OB assays.
Results—Baseline differences in CFU-F, CFU-OB/ALP+, and CFU-OB/total were observed
between the 4 strains. Strain specific responses to ALN and F treatments were observed for CFU-F,
CFU-OB/ALP+, and CFU-OB/total. F treatment alone resulted in decreases in CFU-F (p = 0.013),
CFU-OB/ALP+ (p = 0.005), and CFU-OB/total (p = 0.003) in the C3H strain. CFU-F (p = 0.036)
were decreased by F in the B6 strain. No significant (NS) effects of F were observed for FVB and
BALB. ALN treatment resulted in a significant decrease in CFU-F (p = 0.0014) and CFU-OB/total
(p = 0.028) in C3H only. ALN treatment had NS effect on CFU-OB/ALP+ in all 4 strains.
Conclusion—Genetic factors appear to play a role in ALN's effects on CFU-F and CFU-OB/total
but not on CFU-OB/ALP+.
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Clinical Relevance
There is a rapidly growing population of patients receiving oral and parenteral bisphosphonates
to manage/treat diseases of the bone and in cancer. Concerns have emerged towards unwanted
and potentially serious side effects of bisphosphonate therapy. Successful orthodontics relies
upon orchestrated function of many of the same cells affected by bisphosphonates. There is
great interest to better understand to what extent bisphosphonate therapy may have on
orthodontic treatment and outcome as well as any possibility that orthodontic treatment may
trigger events capable of leading to serious side effects like osteonecrosis of the jaw.
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Nitrogen containing bisphosphonates (BPN) are a major class of bone seeking compounds that
are used for the treatment of bone diseases such as Paget's disease of bone, multiple myeloma,
bone metastases, osteoporosis (adults), and pediatric bone diseases (i.e. osteogenesis
imperfecta). BPNs are stable analogues of naturally occurring inorganic pyrophosphate (PPi)
containing two phosphonate groups attached to a single carbon atom, forming a “P-C-P”
structure. BPNs have high affinity for hydroxyapatite (HAP) crystals and have multiple direct
effects on HAP, including inhibition of calcification, crystal growth, and crystal dissolution.
BPNs have highly selective localization and retention in bone preferentially
compartmentalizing to bone undergoing resorption or formation and can achieve high local
levels (1-3).
Bisphosphonates can inhibit of bone resorption indirectly through impairment of osteoclast
function. The non-nitrogenous bisphosphonates can disrupt osteoclast cellular metabolism and
induce apoptosis (4,5). In long term bone marrow cultures BPNs inhibit osteoclast
differentiation (6,7) and appear to act through osteoblasts to inhibit osteoclast function (7-9).
Despite these actions, BPN's greatest effects on osteoclast function come from inhibition of
farnesyl pyrophosphate synthase (FPPS) within the melavonate pathway (10-12). FPPS
generates isoprenoid lipids during the post translational modification of small GTP-binding
proteins (i.e. Rho, Rac, cdc42, and Rab) important for osteoclast formation, function, and
survival.
As pointed out above bisphosphonates can have actions on osteoblast function.
Bisphosphonates exhibit biphasic effects on osteoblast precursors in vitro—stimulatory at low
doses and inhibitory at higher doses (13,14). At a lower dose/exposure, ALN inhibits osteoblast
apoptosis (15,16) via connexin 43 (17,18). Several investigators also noted that low dose/
exposure of bisphosphonates stimulates osteoblast proliferation and differentiation in vitro
(14,19,20). On the other hand, at a higher dose/exposure, bisphosphonates have been shown
to exhibit no stimulatory effect on osteoblasts (21,22) and suppress bone formation
independently of bone resorption (23). Effects of bisphosphonates, such as ALN, have been
observed to be dose dependent and animal model dependent (24). However, no study has
investigated the dose-dependent modulation of formation of early and late osteoblastic cell
precursors by in vivo ALN treatments with genetic background as a factor. Finally,
bisphsophonates have actions on angiogenesis. Clodronate, risedronate, ibandronate,
pamidronate, and zoledronic acid have anti-angiogenic actions (25-27). Bisphosphonates can
inhibit in vitro proliferation, chemotaxis, circulation, and capillary formation of bone marrow
endothelial cells via VEGF and VEFG receptors (28-30). Furthermore bisphosphonates can
lead to transient reduction in circulating levels of VEGF, bFGF, and Mmp2 following
zolendronate infusion (31).
Bisphosphonates and orthodontic tooth movement
The systemic effects of BPNs on orthodontic tooth movement. Alendronate administered
subcutaneously (s.c.) inhibited tooth movement in rats to 40% of the control (32). A single
intraperitoneal (i.p.) dose of 1500μg/kg of pamidronate prior to orthodontic tooth movement
resulted in impaired osteoclast structure and decreased expression of vacuolar-type H+-
ATPase and cathepsin K (33). Systemic pamidronate administered shortly before removal of
orthodontic force resulted in decreases the extent of initial relapse of orthodontically moved
rat molars (34). Similarly s.c. administration of pamidronate inhibited molar tooth movement
in rats (35). The topical application of risedronate, alendronate or clodronate in the
subperiosteum of following tooth movement prevented relapse of the moved teeth as well as
root resorption (32,36-38). Finally there is in vitro evidence using isolated primary human
periodontal ligament (PDL) cells subjected to mechanical induced stress (compression) that
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clodronate is capable of inhibiting prostaglandin E2 (PGE2), cyclo-oxygenase-2 (COX-2), and
receptor activator of NF-kappa B ligand (RANKL) gene expression (39).
Awareness to potential risks of BPN in orthodontics has been raised (40-42). However, there
are very few case reports in literature of orthodontic treatment of patients who were taking
bisphosphonates, one of which involved only 2 patients (41).
Fluoride
Fluoride is an important micronutrient which, similar to bisphosphonates, preferentially
compartmentalizes to bone and accumulates with deposition (43,44). Fluoride is known for its
anabolic effects on bone and its use as a therapeutic agent for postmenopausal osteoporosis
has been investigated with mixed results (45,46). Fluoride can affect osteoblasts anabolically
in vivo (47) and in vitro (43) through an undetermined mechanism and results in increased bone
mass (43,48). It has been demonstrated using inbred mouse strains that genetic factors play a
role in the effects of fluoride both in dental fluorosis (49) and in variation in bone properties
in response to fluoride exposure (50,51). Yan et al. (52) used B6 and C3H inbred strains of
mice to show that genetic background influences fluoride's effect on osteoclastogenesis. Since
fluoride and bisphosphonate target the same physiological compartment, it is possible that there
may be some interaction between these two agents.
Bone marrow derived MSCs and osteogenic potential
In 1970s, Friedenstein et al. reported that marrow stromal cells/mesenchymal stem cells
(MSC), from the bone marrow, possess the potential to differentiate along multiple
mesenchymal cell lineages, including osteoblast precursors (53-55). A standard liquid culture
system was developed to isolate MSC by their adherence to the plastic of tissue-culture plates,
where clonal populations expand from single precursors—colony-forming-unit fibroblasts
(CFU-F). CFU-F is recognized as the early osteoblastic cell precursors and the CFU-F assay
is a useful method to enumerate the number of MSCs in bone marrow (53-56). With the addition
of ascorbic acid and dexamethasone, the differentiation of the plastic adherent cells can be
modified in vitro at the colony level to give rise to cells capable of forming mineralized nodules
—colony-forming-unit osteoblasts (CFU-OB) (56).
The use of CFU-F and CFU-OB assays provides an opportunity for the assessment of the effects
of in vivo ALN treatment, alone and with fluoride, on early and late osteoblastic cell precursors
from different inbred strains of mice.
Materials and methods
Animals
Male mice of the C57BL/6J (B6), BALB/cByJ (BALB), C3H/HeJ (C3H) and FVB/NJ (FVB)
inbred strains were obtained from The Jackson Laboratory (Bar Harbor, ME) at 5 weeks of
age. Food and water were provided ad libitum. A laboratory rodent diet LabDiet® 5001 (PMI®
Nutrition International) was provided and contained 0.95% calcium, 0.67% phosphorous,
4.5IU/gm vitamin D3, and an average [F] of 6.56 ± 0.28 μg/gm. Mice from each strain were
caged in trios and housed in the Division of Lab Animal Medicine facility within the Dental
Research Center, a fully AAALAC accredited unit, at an ambient temperature of 21°C and
maintained on a 12:12 hr light/dark cycle. All experimental procedures were approved by the
IACUC at the University of North Carolina at Chapel Hill.
ALN and F treatments
A total of 64 mice per strain were used for this study. After 1 week of acclimation, 8 mice per
strain were randomly assigned to one of 8 treatment groups (Group 1 = ALN 3 μg/kg/week; F
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0 ppm; Group 2 = ALN 3 μg/kg/week; F 50 ppm; Group 3 = ALN 30 μg/kg/week; F 0 ppm;
Group 4 = ALN 30 μg/kg/week; F 50 ppm; Group 5 = ALN 150 μg/kg/week; F 0 ppm; Group
6 = ALN 150 μg/kg/week; F 50 ppm; Group 7= ALN 0 μg/kg/week; F 0 ppm; and Group 8 =
ALN 0 μg/kg/week; F 50 ppm).
Fluoride ion (0 or 50ppm) was provided as NaF (Sigma-Aldrich, CAS 7681-49-4) in the
drinking water. Alendronate (ALN) (alendronate sodium, a gift from Merck Research
Laboratories, Rahway, NJ) was prepared in 0.9% w/v NaCl and administered s.c. The 3 and
30μg/kg/week was administered as a single dose and the 150μg/kg/week was administered as
a split dose twice a week. The 3μg/kg/week dose has been previously shown to significantly
increased the number of CFU-F colonies in the bone marrow from young and old animals and
better permit assessment of bone-forming effects of low dose ALN in osteoporosis (14). The
30μg/kg/week dose was shown to stop bone loss in ovariectomized rats (57). The 150μg/kg/
week was considered an equivalent dose for mice to have a maximal effect on osteoclasts
without toxic effects. After 3-weeks treatment mice were euthanized. Bone marrow cells were
flushed and collected from the tibia and femur from one hind leg of each animal.
CFU-F assays
Bone marrow cells were flushed from the femurs and tibiae of mice and plated in triplicate
cultures (six-well plates) at 2 different densities (0.5 × 106 cells/well or 1.0 × 106 cells/well)
using complete media prepared with MesenCult™ Basal Medium and Mesenchymal stem cell
Stimulatory Supplements (StemCell Technologies; Vancouver, BC, Canada). The formation
of CFU-F was evaluated after 14 days of culture in a humidified 5% C02/37°C environment.
Cultures were washed with calcium and magnesium free Dulbecco's phosphate buffered saline
(PBS) twice and then fixed with cold ethanol. CFU-Fs were stained with Giemsa stain and
colonies with >50 cells counted using light microscopy.
CFU-OB assays
The bone marrow cells obtained from the mice were plated in triplicate cultures (six-well plates)
at 2 different densities (0.5 × 106 cells/well or 1.0 × 106 cells/well) as described above. The
complete media used will be prepared from MesenCult™ Basal Medium and Mesenchymal
stem cell Stimulatory Supplements (StemCell Technologies; Vancouver, BC, Canada) plus
50μg/mL of ascorbic acid and 10-8M dexamethasone. After 14 days, the cultures were
terminated by washing with PBS twice and then fixed with cold ethanol. Formation of
osteoblast progenitors was detected using an alkaline phosphatase assay (86-R, Sigma-
Aldrich). Alkaline phosphatase positive colonies were counted. Afterwards the plates were
washed with borate buffer and stained with borate buffer containing 1% w/v methylene blue
for total colonies.
Statistics
Results of the CFU-F and CFU-OB assays were reported as mean ± SD of triplicate cultures.
For each variable, effects across treatment groups were compared using one-way ANOVA.
For comparison of treatment groups in pairs, Student's t-test was used. Adjusted p-values ≤
0.05 were considered significant.
Results
Strain dependent differences in CFU-F, CFU-OB/ALP+, and CFU-OB/total were observed at
baseline (Table 1). BALB mice demonstrated significantly higher mean CFU-F compared to
B6 (p < 0.0001), FVB (p < 0.0001), and C3H (p < 0.001). FVB had the lowest mean CFU-F
and this difference was significant when compared to C3H (p = 0.002) and BALB (p<0.0001)
but not B6. BALB also displayed a significantly higher number of ALP+ CFU-OB than B6 (p
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< 0.0001), C3H (p < 0.001) and FVB (p < 0.001). When the total numbers of CFU-OB were
counted, a greater difference between the strains was noted. BALB had significantly higher
number of CFU-OB/total compared to B6 (p < 0.0001) and FVB (p < 0.001); C3H also
displayed significantly higher number of CFU-OB/total compared to B6 (p = 0.003) and FVB
(p = 0.042). These strain dependent differences in bone marrow derived CFUs were consistent
with reports from others (58,59). Intrinsic differences were again observed in the ratios of the
total CFU-OB that were ALP+ at baseline for each individual strain. BALB and FVB showed
higher ALP+/total CFU-OB ratios compared to B6 (BALB, p = 0.004; FVB, p = 0.006) and
C3H (BALB, p = 0.011; FVB, p = 0.017).
Fluoride alone did not significantly alter the frequency of CFU-F, CFU-OB/ALP+, or CFU-
OB/total for BALB and FVB mice. Significant decreases in mean CFU-F were found in B6 (p
= 0.036) and C3H mice (p = 0.013) treated with 50ppm [F]. Only the C3H strain demonstrated
significant reductions in CFU-OB/ALP+ (p = 0.005) and CFU-OB/total (p = 0.003).
Systemic alendronate had no significant effect on the frequencies of CFU-F, CFU-OB/ALP+,
or CFU-OB/total for the BALB, B6, and FVB strains. Alendronate treatment significantly
reduced CFU-F (p = 0.0014) and CFU-OB/total (p = 0.028) in the C3H strain without affecting
the frequency of CFU-OB/ALP+.
Discussion
In our review of the literature we found that little is known regarding bisphosphonates' action
during orthodontic tooth movement beyond reductions in movement magnitude and reducing
relapse predominantly in animal models (32,34-38). Bisphosphonates have actions on a variety
of cell types including those coordinating angiogenesis. Whereas the majority of studies have
focused upon bisphosphonates' actions on osteoclasts and osteoblasts, we chose to investigate
potential effects of the nitrogen containing bisphosphonate, alendronate in the context of
another bone seeking agent fluoride, on the bone marrow mesenchymal stem cell (MSC) pool.
This study investigated the inter-strain responses to ALN treatment (+/- fluoride). Four strains
of mice, C57BL/6J (B6), BALB/cByJ (BALB), C3H/HeJ (C3H), and FVB/NJ (FVB) were
selected based on differences in genetics, bone biology and wound healing characteristics
(49-52,60,61). This study tested the hypothesis that systemic ALN and fluoride would interact
and affect the bone marrow pool of MSCs capable of forming early (CFU-F) or late (CFU-
OB) osteoprogenitor colonies in a strain-specific manner. While the four strains differed in
baseline frequencies of CFU-F, CFU-OB/ALP+, and CFU-OB/total their responses to fluoride
or alendronate were limited. Fluoride treatment of 50ppm in the drinking water would raise
the serum [F] to a physiologically relevant level of approximately 6-10μM/L (52,62) and had
the most pronounced effect on the C3H strain by reducing CFU-F, CFU-OB/total and CFU-
OB/ALP+ frequency. B6 was the only other strain that responded to F with a reduction in CFU-
F. Alendronate across a wide range of doses resulted in only a modest reduction in CFU-F and
CFU-OB/total in the C3H strain. Given the relatively small number of strains investigated it
would appear that systemic alendronate has minimal effects on bone marrow MSC pool and
no effect on the frequency of ALP+ osteoblast precursor potential.
Acknowledgements
Supported by a grant from the National Institute of Craniofacial and Dental Research DE014853
References
1. Russell RG. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97–106.
[PubMed: 10423031]
Chou et al. Page 5













2. Russell RG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 2006;1068:367–401.
[PubMed: 16831938]
3. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007;119:S150–62.
[PubMed: 17332236]
4. Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ. Clodronate and liposome-
encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-
dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997;12:1358–67.
[PubMed: 9286751]
5. Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ. The molecular mechanism of action of
the antiresorptive and anti-inflammatory drug clodronate: evidence for the formation in vivo of a
metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis
Rheum 2001;44:2201–10. [PubMed: 11592386]
6. Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by
bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989;83:1930–5.
[PubMed: 2524504]
7. Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugal N, et al. Bisphosphonates act on
osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 1996;18:9–14.
[PubMed: 8717530]
8. Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of
osteoclast-mediated resorption. Endocrinology 1996;137:2324–33. [PubMed: 8641182]
9. Yu X, Scholler J, Foged NT. Interaction between effects of parathyroid hormone and bisphosphonate
on regulation of osteoclast activity by the osteoblast-like cell line UMR-106. Bone 1996;19:339–45.
[PubMed: 8894139]
10. Fisher JE, Rodan GA, Reszka AA. In vivo effects of bisphosphonates on the osteoclast mevalonate
pathway. Endocrinology 2000;141:4793–6. [PubMed: 11108295]
11. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Nitrogen-containing bisphosphonates
inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative
potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res
Commun 1999;255:491–4. [PubMed: 10049736]
12. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing
bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-
binding proteins, including Ras. J Bone Miner Res 1998;13:581–9. [PubMed: 9556058]
13. Still K, Phipps RJ, Scutt A. Effects of risedronate, alendronate, and etidronate on the viability and
activity of rat bone marrow stromal cells in vitro. Calcif Tissue Int 2003;72:143–50. [PubMed:
12457261]
14. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G. Bisphosphonates stimulate
formation of osteoblast precursors and mineralized nodules in murine and human bone marrow
cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone
1998;22:455–61. [PubMed: 9600778]
15. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of
osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999;104:1363–
74. [PubMed: 10562298]
16. Plotkin LI, Manolagas SC, Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates
on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone
2006;39:443–52. [PubMed: 16627025]
17. Plotkin LI, Bellido T. Bisphosphonate-induced, hemichannel-mediated, anti-apoptosis through the
Src/ERK pathway: a gap junction-independent action of connexin43. Cell Commun Adhes
2001;8:377–82. [PubMed: 12064622]
18. Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T. Connexin 43 is
required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone
Miner Res. 2008 Jul 2;Epub ahead of print
19. von Knoch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I, et al. Effects of
bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells.
Biomaterials 2005;26:6941–9. [PubMed: 16009417]
Chou et al. Page 6













20. Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and maturation by
bisphosphonates. Biomaterials 2004;25:4105–15. [PubMed: 15046901]
21. Yaffe A, Kollerman R, Bahar H, Binderman I. The influence of alendronate on bone formation and
resorption in a rat ectopic bone development model. J Periodontol 2003;74:44–50. [PubMed:
12593595]
22. Garcia-Moreno C, Serrano S, Nacher M, Farre M, Diez A, Marinoso ML, et al. Effect of alendronate
on cultured normal human osteoblasts. Bone 1998;22:233–9. [PubMed: 9580147]
23. Iwata K, Li J, Follet H, Phipps RJ, Burr DB. Bisphosphonates suppress periosteal osteoblast activity
independently of resorption in rat femur and tibia. Bone 2006;39:1053–8. [PubMed: 16807159]
24. Sama AA, Khan SN, Myers ER, Huang RC, Cammisa FP Jr, Sandhu HS, et al. High-dose alendronate
uncouples osteoclast and osteoblast function: a study in a rat spine pseudarthrosis model. Clin Orthop
Relat Res 2004;425:135–42. [PubMed: 15292798]
25. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit
angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated
rats. Cancer Res 2002;62:6538–44. [PubMed: 12438248]
26. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, et al. Pamidronate induces
modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002;8:1080–
4. [PubMed: 12006522]
27. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects
of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055–61.
[PubMed: 12183663]
28. Allegra A, Oteri G, Nastro E, Alonci A, Bellomo G, Del Fabro V, et al. Patients with bisphosphonates-
associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol
2007;25:164–9. [PubMed: 17577204]
29. Hasmim M, Bieler G, Ruegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival
through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost
2007;5:166–73. [PubMed: 17059425]
30. Scavelli C, Di Pietro G, Cirulli T, Coluccia M, Boccarelli A, Giannini T, et al. Zoledronic acid affects
over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther
2007;6:3256–62. [PubMed: 18089719]
31. Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S, et al. Zoledronic-acid-induced
circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory
cytokines in metastatic breast cancer patients. Oncology 2005;69:35–43. [PubMed: 16088233]
32. Igarashi K, Mitani H, Adachi H, Shinoda H. Anchorage and retentive effects of a bisphosphonate
(AHBuBP) on tooth movements in rats. Am J Orthod Dentofacial Orthop 1994;106:279–89.
[PubMed: 8074093]
33. Sato Y, Sakai H, Kobayashi Y, Shibasaki Y, Sasaki T. Bisphosphonate administration alters
subcellular localization of vacuolar-type H(+)-ATPase and cathepsin K in osteoclasts during
experimental movement of rat molars. Anat Rec 2000;260:72–80. [PubMed: 10967538]
34. Kim TW, Yoshida Y, Yokoya K, Sasaki T. An ultrastructural study of the effects of bisphosphonate
administration on osteoclastic bone resorption during relapse of experimentally moved rat molars.
Am J Orthod Dentofacial Orthop 1999;115:645–53. [PubMed: 10358247]
35. Keles A, Grunes B, Difuria C, Gagari E, Srinivasan V, Darendeliler MA, et al. Inhibition of tooth
movement by osteoprotegerin vs. pamidronate under conditions of constant orthodontic force. Eur J
Oral Sci 2007;115:131–6. [PubMed: 17451503]
36. Adachi H, Igarashi K, Mitani H, Shinoda H. Effects of topical administration of a bisphosphonate
(risedronate) on orthodontic tooth movements in rats. J Dent Res 1994;73:1478–86. [PubMed:
8083446]
37. Igarashi K, Adachi H, Mitani H, Shinoda H. Inhibitory effect of the topical administration of a
bisphosphonate (risedronate) on root resorption incident to orthodontic tooth movement in rats. J
Dent Res 1996;75:1644–9. [PubMed: 8952616]
38. Liu L, Igarashi K, Haruyama N, Saeki S, Shinoda H, Mitani H. Effects of local administration of
clodronate on orthodontic tooth movement and root resorption in rats. Eur J Orthod 2004;26:469–
73. [PubMed: 15536834]
Chou et al. Page 7













39. Liu L, Igarashi K, Kanzaki H, Chiba M, Shinoda H, Mitani H. Clodronate inhibits PGE(2) production
in compressed periodontal ligament cells. J Dent Res 2006;85:757–60. [PubMed: 16861295]
40. Keim RG. Bisphosphonates in orthodontics. J Clin Orthod 2006;40:403–4. [PubMed: 16902255]
41. Rinchuse DJ, Rinchuse DJ, Sosovicka MF, Robison JM, Pendleton R. Orthodontic treatment of
patients using bisphosphonates: a report of 2 cases. Am J Orthod Dentofacial Orthop 2007;131:321–
6. [PubMed: 17346586]
42. Zahrowski JJ. Bisphosphonate treatment: an orthodontic concern calling for a proactive approach.
Am J Orthod Dentofacial Orthop 2007;131:311–20. [PubMed: 17346585]
43. Farley JR, Wergedal JE, Baylink DJ. Fluoride directly stimulates proliferation and alkaline
phosphatase activity of bone-forming cells. Science 1983;222:330–2. [PubMed: 6623079]
44. Palmer C, Wolfe SH. American Dietetic A. Position of the American Dietetic Association: the impact
of fluoride on health. J Am Diet Assoc 2005;105:1620–8. [PubMed: 16183366]
45. Haguenauer D, Welch V, Shea B, Tugwell P, Adachi JD, Wells G. Fluoride for the treatment of
postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 2000;11:727–38. [PubMed:
11148800]
46. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, et al. Meta-analyses of therapies for
postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal
osteoporosis. Endocri Rev 2002;23:570–8.
47. Turner CH, Garetto LP, Dunipace AJ, Zhang W, Wilson ME, Grynpas MD, et al. Fluoride treatment
increased serum IGF-1, bone turnover, and bone mass, but not bone strength, in rabbits. Calcif Tissue
Int 1997;61:77–83. [PubMed: 9192519]
48. Lau KH, Baylink DJ. Molecular mechanism of action of fluoride on bone cells. J Bone Miner Res
1998;13:1660–7. [PubMed: 9797473]
49. Everett ET, McHenry MA, Reynolds N, Eggertsson H, Sullivan J, Kantmann C, et al. Dental fluorosis:
variability among different inbred mouse strains. J Dent Res 2002;81:794–8. [PubMed: 12407097]
50. Mousny M, Banse X, Wise L, Everett ET, Hancock R, Vieth R, et al. The genetic influence on bone
susceptibility to fluoride. Bone 2006;39:1283–9. [PubMed: 16920415]
51. Mousny M, Omelon S, Wise L, Everett ET, Dumitriu M, Holmyard DP, et al. Fluoride effects on
bone formation and mineralization are influenced by genetics. Bone 2008;43:1064–74.
52. Yan D, Gurumurthy A, Wright M, Pfeiler TW, Loboa EG, Everett ET. Genetic background influences
fluoride's effects on osteoclastogenesis. Bone 2007;41:1036–44. [PubMed: 17936699]
53. Friedenstein AJ. Precursor cells of mechanocytes. Int Rev Cytol 1976;47:327–59. [PubMed: 11195]
54. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse
hematopoietic organs. Exp Hematol 1976;4:267–74. [PubMed: 976387]
55. Friedenstein AJ, Chailakhyan RK, Gerasimov UV. Bone marrow osteogenic stem cells: in vitro
cultivation and transplantation in diffusion chambers. Cell Tissue Kinet 1987;20:263–72. [PubMed:
3690622]
56. Owen M, Friedenstein AJ. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found
Symp 1988;136:42–60. [PubMed: 3068016]
57. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S. Time-dependent changes in
biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl,
tamoxifen, estrogen, and alendronate. Bone 1996;18:621–7. [PubMed: 8806005]
58. Dimai HP, Linkhart TA, Linkhart SG, Donahue LR, Beamer WG, Rosen CJ, et al. Alkaline
phosphatase levels and osteoprogenitor cell numbers suggest bone formation may contribute to peak
bone density differences between two inbred strains of mice. Bone 1998;22:211–6. [PubMed:
9514213]
59. Phinney DG, Kopen G, Isaacson RL, Prockop DJ. Plastic adherent stromal cells from the bone marrow
of commonly used strains of inbred mice: variations in yield, growth, and differentiation. J Cell
Biochem 1999;72:570–85. [PubMed: 10022616]
60. Al-Qawasmi RA, Hartsfield JK Jr, Everett ET, Weaver MR, Foroud TM, Faust DM, et al. Root
resorption associated with orthodontic force in inbred mice: genetic contributions. Eur J Orthod
2006;28:13–9. [PubMed: 16373453]
Chou et al. Page 8













61. Beamer WG, Donahue LR, Rosen CJ. Genetics and bone. Using the mouse to understand man. J
Musculoskelet Neuronal Interact 2002;2:225–31. [PubMed: 15758440]
62. Everett ET, Yan D, Weaver M, Liu L, Foroud T, Martinez-Mier EA. Detection of dental fluorosis-
associated quantitative trait loci on mouse chromosomes 2 and 11. Cells Tissues Organs
2008;189:212–17. [PubMed: 18701810]
Chou et al. Page 9

































































































































































































































































































































































































































































































































































































































































































































































































































































































































Orthod Craniofac Res. Author manuscript; available in PMC 2010 May 1.
